Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced HER2+Breast Cancer × Breast × 90 days × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1150 Triple Negative Breast Neoplasms 198 Ovarian Neoplasms 101 Prostatic Neoplasms 82 Carcinoma, Non-Small-Cell Lung 81 Neoplasms 77 Colorectal Neoplasms 77 Lung Neoplasms 68 Neoplasm Metastasis 67 Endometrial Neoplasms 57 Pancreatic Neoplasms 53 Melanoma 52 Stomach Neoplasms 44 Uterine Cervical Neoplasms 43 Squamous Cell Carcinoma of Head and Neck 41 Head and Neck Neoplasms 32 Carcinoma, Intraductal, Noninfiltrating 32 Urinary Bladder Neoplasms 29 Colonic Neoplasms 27 Sarcoma 26 Breast Carcinoma In Situ 26 Esophageal Neoplasms 25 Carcinoma, Renal Cell 24 Motor Activity 23 Brain Neoplasms 21 Small Cell Lung Carcinoma 19 Liver Neoplasms 16 Lymphoma 15 Anatomic Stage I Breast Cancer AJCC v8 15 Carcinoma, Hepatocellular 14

Interventions

pertuzumab 1 Trastuzumab 1 Alpelisib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04208178 2026-02-02

EPIK-B2

Novartis

Phase 3 Active not recruiting

Advanced HER2+Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡